Table 1.
Details of the Plasmodium spp. proteins expressed in this study
| Sp. | Official nomenclature | Synonym/s | Accession number | Region expressed | Length (aa) | Exp. level | PlasmoDB, previous ID | Addgene ID |
|---|---|---|---|---|---|---|---|---|
| P. falciparum | MSP1* | MSA1, Pf190, Pf195 | PF3D7_0930300 | V20-S1701 | 1682 | Low | Merozoite surface protein 1 | 47709 |
| AMA1* | Pf83, RMA1, PfAMA1 | PF3D7_1133400 | Q25-T541 | 517 | High | Apical membrane antigen 1, PF11_0344 | 47741 | |
| P92* | Pf92 | PF3D7_1364100 | A26-S770 | 745 | Low | 6-cysteine protein, PF13_0338 | 47728 | |
| MSP4 | PF3D7_0207000 | Y29-S253 | 225 | Low | Merozoite surface protein 4, PFB0310C | 47717 | ||
| MSP5 | PF3D7_0206900.1 | N22-S251 | 230 | Low | Merozoite surface protein 5, PFB0305C | 47718 | ||
| P12* | Pf12, Pfs12 | PF3D7_0612700 | H26-S323 | 298 | High | 6-cysteine protein, MAL6P1, PFF0615C | 47725 | |
| GAMA | PSOP9 | PF3D7_0828800 | L22-P710 | 689 | Med | GPI-anchored micronemal antigen | 47747 | |
| MSP10* | PF3D7_0620400 | H27-S503 | 477 | Med | Merozoite surface protein 10, MAL6P1.221, PFF0995C | 47719 | ||
| P38 | Pf38, Pfs38 | PF3D7_0508000 | Q22-S328 | 307 | High | 6-cysteine protein, PFE0395C | 47727 | |
| MSP3.1* | MSP3, SPAM | PF3D7_1035400 | K26-H354 | 328 | Med | Merozoite surface protein 3, PF10_0345 | 47731 | |
| P41 | Pf41, Pfs41 | PF3D7_0404900 | K21-S378 | 358 | High | 6-cysteine protein, PFD0240C | 47739 | |
| MSP7 | PF3D7_1335100 | T28-M351 | 324 | Med | Merozoite surface protein 7, PF13_0197 | 47735 | ||
| HPzz* | PFA0210c | PF3D7_0104200 | Y24-D466 | 443 | Low | StAR-related lipid transfer protein, MAL1P1.33 | 50821 | |
| P. vivax | MSP4 | PVX_003775 | A26-S227 | 202 | Low | Merozoite surface protein 4, putative, PV003775 | 68510 | |
| MSP5* | PVX_003770 | R22-S367 | 346 | Med | Merozoite surface protein 5, PV003770 | 68511 | ||
| P12* | PVX_113775 | F24-A339 | 316 | Med | 6-cysteine protein, PV113775 | 68516 | ||
| GAMA | PVX_088910 | L21-S749 | 729 | Med | GPI-anchored micronemal antigen, putative, PV088910 | 68522 | ||
| CyRPA | PVX_090240 | T23-D366 | 344 | Med | Cysteine-rich protective antigen, putative, PV090240 | 68525 | ||
| HPzz* | PVX_081550 | R23-F495 | 473 | Low | StAR-related lipid transfer protein, putative, PV081550 | 68532 | ||
| P38* | PVX_097960 | K29-G334 | 306 | Med | 6-cysteine protein, PV097960 | 68518 | ||
| MSP7.1* | PVX_082700 | E22-Y420 | 399 | Med | Merozoite surface protein 7 (MSP7), PV082700 | 68512 | ||
| MSP3γ | MSP3.1 | PVX_097670 | N21-K845 | 825 | Med | Merozoite surface protein 3, PV097670 | 68506 | |
| P41* | PVX_000995 | E22-E384 | 363 | Med | 6-cysteine protein, PV000995 | 68519 | ||
| P. malariae | CyRPA | PmUG01_05040800 | E20-D358 | 339 | Low | Cysteine-rich protective antigen, putative | 126817 | |
| GAMA | PmUG01_05017200 | L22-S764 | 743 | High | GPI-anchored micronemal antigen | 126818 | ||
| MSP10* | PmUG01_11043200 | N27-S389 | 363 | Low | Merozoite surface protein 10, putative | 126819 | ||
| MSP4 | PmUG01_04025600 | Y29-S206 | 178 | Low | Merozoite surface protein 4, putative | 126820 | ||
| MSP5* | PmUG01_04025700 | K22-L291 | 270 | High | Merozoite surface protein 5 | 126821 | ||
| P12 | P12p | PmUG01_11050400 | Y19-S333 | 315 | Low | 6-cysteine protein | 126822 | |
| P38 | PmUG01_06016900 | M1-A310 | 310 | Low | 6-cysteine protein, putative | 126823 | ||
| P41* | PmUG01_03015000 | Q23-D374 | 352 | Med | 6-cysteine protein, putative | 126824 | ||
| MSP3.10 | PmUG01_06022000 | K24-I525 | 522 | High | Merozoite surface protein 3, putative | 126825 | ||
| MSP3.5 | PmUG01_06022600 | N21-S562 | 542 | High | Merozoite surface protein 3, putative | 126826 | ||
| MSP7.1 | PmUG01_12029500 | R25-I442 | 418 | High | MSP7-like protein, putative | 126827 | ||
| MSP7.4 | PmUG01_12029900 | K22-V394 | 373 | High | MSP7-like protein, putative | 126828 | ||
| P. ovale | CyRPA | POVCU1_054880 | S20-D359 | 340 | Med | Cysteine-rich protective antigen, putative, SBS99762.1 | 126829 | |
| GAMA | PocGH01_05012100 | L22-S755 | 734 | High | GPI-anchored micronemal antigen, putative | 126830 | ||
| MSP10* | PocGH01_11036900 | Y27-S430 | 404 | High | Merozoite surface protein 10, putative | 126831 | ||
| MSP4 | PocGH01_04023000 | N26-S209 | 184 | High | Merozoite surface protein 4, putative | 126832 | ||
| MSP5 | PocGH01_04023100 | F20-S311 | 292 | High | Merozoite surface protein 5, putative | 126833 | ||
| P12 | P12p | PocGH01_11044100 | E23-S301 | 279 | Low | 6-cysteine protein | 126834 | |
| P38 | PocGH01_10033500 | K25-S332 | 308 | Low | 6-cysteine protein, putative | 126835 | ||
| P41* | PocGH01_03012400 | E16-E375 | 360 | Med | 6-cysteine protein, putative | 126836 | ||
| MSP3.5* | PocGH01_10038700 | K24-P480 | 457 | Med | Merozoite surface protein 3, putative | 126837 | ||
| MSP3.6 | PocGH01_10038800 | K24-S732 | 709 | Low | Merozoite surface protein 3, putative | 126838 | ||
| MSP7.12 | PocGH01_12028800 | K23-T441 | 419 | Med | MSP7-like protein, putative | 126839 | ||
| MSP7.8 | PocGH01_12028400 | K23-T379 | 357 | Med | MSP7-like protein, putative | 126840 | ||
| P. knowlesi | CyRPA | PKNH_0515800 | N23-E366 | 344 | Med | Cysteine-rich protective antigen, putative, PKH_052740 | 126841 | |
| GAMA | PSOP9 | PKNH_1322900 | L21-S700 | 680 | Med | GPI-anchored micronemal antigen, putative, PKH_050210 | 126842 | |
| MSP10* | PKNH_1129800 | N27-S417 | 391 | High | Merozoite surface protein 10, putative, PKH_112880 | 126940 | ||
| MSP4 | PKNH_0414100 | D26-S182 | 157 | Med | Merozoite surface protein 4, putative, PKH_041300 | 126843 | ||
| MSP5 | PKNH_0414200 | H22-S354 | 333 | Med | Merozoite surface protein 5, PKH_041310 | 126844 | ||
| P12* | PKNH_1137300 | F24-S323 | 300 | Med | 6-cysteine protein, PKH_113620 | 126845 | ||
| P38* | PKNH_1025600 | K3-S367 | 365 | Low | 6-cysteine protein, PKH_102490 | 126846 | ||
| P41 | PKNH_0303000 | E22-E393 | 372 | High | 6-cysteine protein, PKH_030970 | 126847 | ||
| P92 | PKNH_1107200 | D24-P857 | 834 | Med | 6-cysteine protein, PKH_110660 | 126848 |
Protein expression plasmids encoding the named genes from the five Plasmodium species that infect humans are detailed. ‘Region expressed’ refers to the ectodomain regions between the predicted signal sequence peptide and the transmembrane or GPI anchor sequence (if present). Expression levels are given as a guide only given the significant batch-to-batch variability observed using this approach and grouped into ‘high’ (between 5 and 50 μg/mL), ‘medium’ (0.5–5 μg/mL) and ‘low’ (0.005–0.5 μg/mL). Those proteins selected for further serological analysis are marked with an asterisk